drugset / Trial / NCT01444092

Safety Study of Entocort for Children With Crohn's Disease

NCT01444092 ↗

Phase 3 Completed 123 enrolled Padagis LLC
NaSingle-groupOpen-labelTreatment

Summary

A Safety Study using Entocort EC for children with mild to moderate Crohn's Disease

Timeline

Start
2011-11
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 6 mg Oral
Subject Budesonide Small molecule 9 mg Oral

Indications